StockData
Aktis Oncology, Inc. logo

Aktis Oncology, Inc. (AKTS) stock

AKTSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026
$16.31+0.15 (+0.93%)

Close on Nov 17, 2026Market cap $907.15MP/E –Yield –

Aktis Oncology cash

Cash and short-term investments held at the end of each period.

Aktis Oncology's cash was $492.90M at Sep 30, 2026. For fiscal 2025 it was $37.78M, down 1.4% from the year before.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$37.78M-1.4%
FY2024Dec 31, 2024$38.31M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$492.90M+173.4%
Q2 FY2026Jun 30, 2026$517.30M+369.4%
Q1 FY2026Mar 31, 2026$538.50M+824.5%
Q4 FY2025Dec 31, 2025$37.78M-1.4%
Q3 FY2025Sep 30, 2025$180.25M–
Q2 FY2025Jun 30, 2025$110.22M–
Q1 FY2025Mar 31, 2025$58.25M–
Q4 FY2024Dec 31, 2024$38.31M–

More Aktis Oncology figures

See a number that looks wrong?